Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to DiffuseSandbox, its self-serve protein ...
By adding AI-enabled RNA design and active learning, Eclipsebio extends its sequencing-based analytics platform into a fully ...
Eclipsebio has acquired Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics.
There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment. Dubbed Muse, ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...
BOSTON--(BUSINESS WIRE)--Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing ...
GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Nate Bek on Jul 25, 2023 at 6:00 am ...
Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
AI systems are only as fair and safe as the data they’re built on. While conversations about AI ethics often focus on model architecture, algorithmic transparency or deployment oversight, fairness and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results